Tags

Type your tag names separated by a space and hit enter

Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
Am J Otolaryngol. 2007 Mar-Apr; 28(2):78-82.AJ

Abstract

PURPOSE

The aim of this study was to compare the efficacy and safety of moxifloxacin with that of amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults.

MATERIALS AND METHODS

Five hundred seventy-five patients from Latin American countries were randomized to receive oral moxifloxacin 400 mg once daily for 7 days, or oral amoxicillin/clavulanate 500/125 mg 3 times daily for 10 days, in a prospective, open study.

RESULTS

At the test-of-cure visit (7-14 days after the end of therapy), the clinical success rate in the moxifloxacin group was 93.4% similar to that in the amoxicillin/clavulanate group (92.7%). Documented bacteriological eradication plus presumed eradication rates in the moxifloxacin (96.5%) and the amoxicillin/clavulanate (96.7%) groups were also similar. Drug-related adverse events were recorded in 32.2% of patients in the moxifloxacin group and 29.7% in the amoxicillin/clavulanate group. Patient discontinuation in the trial due to adverse events occurred for 10 patients in the moxifloxacin group and 6 in the amoxicillin/clavulanate group.

CONCLUSIONS

Overall, in terms of clinical and bacteriological response, moxifloxacin was equivalent to amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults.

Authors+Show Affiliations

Hospital General Dr. Manuel Gea González, Mexico City, Mexico.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17362810

Citation

Arrieta, José R., et al. "Moxifloxacin Vs Amoxicillin/clavulanate in the Treatment of Acute Sinusitis." American Journal of Otolaryngology, vol. 28, no. 2, 2007, pp. 78-82.
Arrieta JR, Galgano AS, Sakano E, et al. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol. 2007;28(2):78-82.
Arrieta, J. R., Galgano, A. S., Sakano, E., Fonseca, X., Amábile-Cuevas, C. F., Hernández-Oliva, G., Vivar, R., González, G., & Torres, A. (2007). Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. American Journal of Otolaryngology, 28(2), 78-82.
Arrieta JR, et al. Moxifloxacin Vs Amoxicillin/clavulanate in the Treatment of Acute Sinusitis. Am J Otolaryngol. 2007 Mar-Apr;28(2):78-82. PubMed PMID: 17362810.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. AU - Arrieta,José R, AU - Galgano,Alejandro S, AU - Sakano,Eulalia, AU - Fonseca,Ximena, AU - Amábile-Cuevas,Carlos F, AU - Hernández-Oliva,Gerardo, AU - Vivar,Raul, AU - González,Gerardo, AU - Torres,Arturo, AU - ,, PY - 2006/03/03/received PY - 2007/3/17/pubmed PY - 2007/5/18/medline PY - 2007/3/17/entrez SP - 78 EP - 82 JF - American journal of otolaryngology JO - Am J Otolaryngol VL - 28 IS - 2 N2 - PURPOSE: The aim of this study was to compare the efficacy and safety of moxifloxacin with that of amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults. MATERIALS AND METHODS: Five hundred seventy-five patients from Latin American countries were randomized to receive oral moxifloxacin 400 mg once daily for 7 days, or oral amoxicillin/clavulanate 500/125 mg 3 times daily for 10 days, in a prospective, open study. RESULTS: At the test-of-cure visit (7-14 days after the end of therapy), the clinical success rate in the moxifloxacin group was 93.4% similar to that in the amoxicillin/clavulanate group (92.7%). Documented bacteriological eradication plus presumed eradication rates in the moxifloxacin (96.5%) and the amoxicillin/clavulanate (96.7%) groups were also similar. Drug-related adverse events were recorded in 32.2% of patients in the moxifloxacin group and 29.7% in the amoxicillin/clavulanate group. Patient discontinuation in the trial due to adverse events occurred for 10 patients in the moxifloxacin group and 6 in the amoxicillin/clavulanate group. CONCLUSIONS: Overall, in terms of clinical and bacteriological response, moxifloxacin was equivalent to amoxicillin/clavulanate for the treatment of acute bacterial sinusitis in adults. SN - 0196-0709 UR - https://www.unboundmedicine.com/medline/citation/17362810/Moxifloxacin_vs_amoxicillin/clavulanate_in_the_treatment_of_acute_sinusitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0196-0709(06)00124-4 DB - PRIME DP - Unbound Medicine ER -